Clinical Trial Update: Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating 5.0% lifitegrast ophthalmic solution for dry eye disease in contact lens wearers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contact Lens Dry Eye
• Dry Eye Disease

Drugs mentioned

• lifitegrast ophthalmic solution 5.0% (lifitegrast)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Contact Lens Dry Eye | Phase 4 | Status: WITHDRAWN